


## AMENDMENTS TO THE SPECIFICATION

Please amend the specification by replacing the paragraph beginning at page 9, line 8 and ending at the last line of page 9 with the following:


The present invention also concerns methods and compositions for the prophylactic and therapeutic treatment of retinal neovascularization and related diseases with other MMP inhibitors, which include the hydroxamic acid-based compounds described in U.S. Patent No. 5,240,958[[.]], which includes compounds of the general formula:



wherein:

R<sup>1</sup> represents a hydrogen atom, C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl, thienyl, substituted phenyl, phenyl(C<sub>1</sub>-C<sub>6</sub>)alkyl, heterocyclyl, (C<sub>1</sub>-C<sub>6</sub>)alkylcarbonyl, phenacyl or substituted phenacyl group; or, when n=O, R<sup>1</sup> represents SR<sup>x</sup>, wherein R<sup>x</sup> represents a group:

R<sup>2</sup> represents a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkenyl, phenyl(C<sub>1</sub>-C<sub>6</sub>) alkyl,



cycloalkyl(C<sub>1</sub>-C<sub>6</sub>)alkyl or cycloalkenyl(C<sub>1</sub>-C<sub>6</sub>)alkyl group;

R<sup>3</sup> represents an amino acid side chain or a C<sub>1</sub>-C<sub>6</sub> alkyl, benzyl, (C<sub>1</sub>-C<sub>6</sub> alkoxy) benzyl, benzyloxy(C<sub>1</sub>-C<sub>6</sub>) or benzyloxybenzyl group;

R<sup>4</sup> represents a hydrogen atom or a C<sub>1</sub>-C<sub>6</sub> alkyl group;

R<sup>5</sup> represents a hydrogen atom or a methyl group;

n is an integer having the value 0, 1 or 2; and

A represents a C<sub>1</sub>-C<sub>6</sub> hydrocarbon chain, optionally substituted with one or more C<sub>1</sub>-C<sub>6</sub> alkyl, phenyl or substituted phenyl groups;

or a salt thereof.

As used herein the term "C<sub>1</sub>-C<sub>6</sub> alkyl" refers to a straight or branched chain alkyl moiety having from one to six carbon atoms, including for example, methyl, ethyl, propyl, isopropyl, butyl, t-butyl, pentyl and hexyl, and cognate terms (such as "C<sub>1</sub>-C<sub>6</sub> alkoxy") are to be construed accordingly.

The term "C<sub>1</sub>-C<sub>6</sub> alkenyl" refers to a straight or branched chain alkyl moiety having one to six carbons and having in addition one double bond, of either E or Z stereochemistry where applicable. This term would include, for example, an alpha, beta-unsaturated methylene group, vinyl, 1-propenyl, 1- and 2-butenyl and 2-methyl-2-propenyl.

The term "cycloalkyl" refers to a saturated alicyclic moiety having from 3 to 8 carbon atoms and includes for example, cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl.

The term "cycloalkenyl" refers to an unsaturated alicycle having from 3 to 8 carbon atoms and includes cyclopropenyl, cyclobutenyl and cyclopentenyl, cyclohexenyl.

The term "substituted", as applied to a phenyl or other aromatic ring, means substituted with up to four substituents each of which independently may be C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkoxy,

hydroxy, thiol, C<sub>1</sub>-C<sub>6</sub> alkylthiol, amino, halo (including fluoro, chloro, bromo and iodo), trifluoromethyl or nitro.

The term "amino acid side chain" means a characteristic side chain attached to the -CH(NH<sub>2</sub>)(COOH) moiety in the following R or S amino acids: glycine, alanine, valine, leucine, isoleucine, phenylalanine, tyrosine, tryptophan, serine, threonine, cysteine, methionine, asparagine, glutamine, lysine, histidine, arginine, glutamic acid and aspartic acid.

The term "hydrocarbon chain" includes alkylene, alkenylene and alkynylene chains of from 1 to 6 carbon atoms. Preferably the carbon atom of the hydrocarbon chain nearest to the hydroxamic acid group is a methylene carbon atom.

There are several chiral centres in the compounds according to the invention because of the presence of asymmetric carbon atoms. The presence of several asymmetric carbon atoms gives rise to a number of diastereomers with the appropriate R or S stereochemistry at each chiral centre. General formula I and, where appropriate, all other formulae in this specification are to be understood to include all such stereoisomers and mixtures (for example racemic mixtures) thereof. Compounds in which the chiral centre adjacent the substituent R<sup>3</sup> has S stereochemistry and/or the chiral centre adjacent the substituent R<sup>2</sup> has R stereochemistry are preferred.

\_\_\_\_\_ Particularly preferred compounds are those having the general formula:

